A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer

NCT07283198 | Not Yet Recruiting Phase 2

• 1 other identifier: JSKN033-201
• Study Type: interventional
• Target: 160
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is an open-label, multicenter, Phase II clinical study designed to evaluate the safety and efficacy of JSKN033 in the treatment of patients with advanced NSCLC. The study is divided into two phases: Part 1 (Dose Selection) and Part 2 (Cohort Expansion). Enrolled subjects are patients with locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) NSCLC who are not eligible for curative treatment. Part 1 (Dose Selection): It consists of two dose groups, with a maximum of 20 subjects enrolled in each group. Part 2 (Cohort Expansion): It consists of two cohorts, with a maximum of 60 subjects enrolled in each cohort.

Conditions

Non Small Cell Lung Cancer (NSCLC)

Outcome Measures

Primary Outcomes (2)

• Number and Severity of Treatment-emergent Adverse Events (TEAEs)

  The incidence and severity of TEAEs and TRAEs (Treatment-related Adverse Events, graded according to NCI CTCAE 5.0), Serious AEs (SAEs), laboratory tests, etc.

  Baseline up to 30 days after the last dose of study drug, up to 1 year

• Objective response rate (ORR)

  ORR was defined as the proportion of subjects achieving Complete Response (CR) or Partial Response (PR)

  Up to 1 year after the last participant receives the last dose

Secondary Outcomes (15)

• Duration of response (DoR)

  Up to 1 year after the last participant receives the last dose

• Disease control rate (DCR)

  Up to 1 year after the last participant receives the last dose

• Clinical benefit rate (CBR)

  Up to 1 year after the last participant receives the last dose

• Progression-free Survival (PFS)

  Up to 1 year after the last participant receives the last dose

• Overall survival (OS)

  Up to 1 year after the last participant receives the last dose

Other Outcomes (1)

• Correlation between biomarkers (HER2 mutation status, HER2/PD-L1 expression levels) in tumor tissue samples and efficacy.

  Up to 1 year after the last participant receives the last dose

Study Arms (1)

Part 1 (Dose Selection) and Part 2 (Cohort Expansion)

EXPERIMENTAL

JSKN033 is administered at the predefined dose, once per treatment cycle.

Drug: JSKN033 Injection

Interventions

JSKN033 Injection DRUG

JSKN033 is a fixed-dose combination consisting of JSKN003 (a HER2-targeted ADC) and envafolimab (a PD-L1 inhibitor)

Part 1 (Dose Selection) and Part 2 (Cohort Expansion)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects can understand the informed consent form,voluntarily participate in the study, and sign the informed consent form.
• Subjects are≥18 years old on the day of signing the informed consent form, regardless of gender.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
• Expected survival time ≥3 months.
• Histologically or cytologically confirmed locally advanced or metastatic NSCLC (per AJCC 8th Edition Lung Cancer TNM Staging) that is not eligible for curative surgery and/or curative radiotherapy.
• NSCLC confirmed to be no other known driver gene alterations for which first- line targeted therapy has been approved.
• For Part 1(Dose Selection): Enrolled subjects are those with advanced unresectable or metastatic NSCLC who have failed or are intolerant to standard previous treatments, and have HER2 mutation or HER2 expression in tumor tissue.
• For Part 2 (Cohort Expansion): Enrolled subjects are those with locally advanced or metastatic NSCLC who have not received prior systemic anti-tumor treatment for their advanced disease.
• Per RECIST 1.1 criteria,subjects have at least one extracranial measurable lesion at baseline.
• Subjects must provide tumor tissue samples.
• Sufficient organ function.
• Female subjects of childbearing potential or male subjects whose partners are of childbearing potential agree to use highly effective contraceptive measures from the time of signing the informed consent form until 24 weeks after the last dose.

You may not qualify if:

• Presence of any small cell carcinoma component in the histological pathology.
• History of other malignant tumors within 5 years prior to the first dose administration.
• History of brainstem, meningeal, or spinal cord metastases/compression, or carcinomatous meningitis; presence of active brain metastases.
• Imaging during the screening phase shows tumor invasion, compression, or location in surrounding vital organs.
• Sufficient washout period from previous treatments prior to the first dose.
• Presence of the following lung diseases or medical history leading to severe respiratory impairment.
• Presence of risk factors related to interstitial lung disease (ILD) or non-infectious pneumonia.
• Presence of cardiovascular and cerebrovascular diseases or risk factors.
• Presence of uncontrolled infections.
• Toxicity from previous anti-tumor treatment has not recovered to grade≤1 (per CTCAE v5.0).
• Previous history of allogeneic bone marrow or organ transplantation.
• Known allergy to any component of the study drug.
• Pregnant and/or lactating women, or women planning to become pregnant during the study.

Sponsors & Collaborators

• Jiangsu Alphamab Biopharmaceuticals Co., Ltd: lead

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Lin Wu, Doctor

CONTACT

+86 731 8976 2300; wulin-calf@vip.163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 2, 2025
• First Posted: December 15, 2025
• Study Start: December 10, 2025
• Primary Completion (Estimated): August 30, 2027
• Study Completion (Estimated): August 30, 2027
• Last Updated: December 15, 2025

Record last verified: 2025-12